The unmet need in rheumatology: reports from the Targeted Therapies meeting 2016.
暂无分享,去创建一个
M. Dougados | D. M. van der Heijde | V. Strand | D. Furst | M. Weinblatt | X. Mariette | G. Burmester | P. Mease | J. Smolen | M. Crow | J. Kalden | K. Winthrop | J. Kay | M. Buch | J. Bathon | F. Breedveld
[1] C. Salvarani,et al. Tocilizumab for the treatment of giant cell arteritis , 2018, Expert review of clinical immunology.
[2] A. Vissink,et al. The microbiome-systemic diseases connection. , 2016, Oral diseases.
[3] D. Symmons,et al. Predictors and outcomes of sustained, intermittent or never achieving remission in patients with recent onset inflammatory polyarthritis: results from the Norfolk Arthritis Register , 2016, Rheumatology.
[4] S. Yount,et al. Patient-Reported Outcomes in Systemic Lupus Erythematosus. , 2016, Rheumatic diseases clinics of North America.
[5] Jinming Li,et al. Diagnostic Value of Serum IgG4 for IgG4-Related Disease , 2016, Medicine.
[6] P. Kiely. Biologic efficacy optimization--a step towards personalized medicine. , 2016, Rheumatology.
[7] A. Yoshimura,et al. Critical Link Between Epigenetics and Transcription Factors in the Induction of Autoimmunity: a Comprehensive Review , 2016, Clinical Reviews in Allergy & Immunology.
[8] Y. Barenholz,et al. A liposomal steroid nano-drug for treating systemic lupus erythematosus , 2016, Lupus.
[9] A. Mahajan,et al. Clearance Deficiency and Cell Death Pathways: A Model for the Pathogenesis of SLE , 2016, Front. Immunol..
[10] J. Orazem,et al. Impact of Out-of-Pocket Costs on Prescription Fills Among New Initiators of Biologic Therapies for Rheumatoid Arthritis , 2016, Journal of managed care & specialty pharmacy.
[11] H. Ueno,et al. T follicular helper (Tfh) cells in lupus: Activation and involvement in SLE pathogenesis , 2016, European journal of immunology.
[12] O. FitzGerald,et al. Psoriatic arthritis: complexities, comorbidities and implications for the clinic , 2016, Expert review of clinical immunology.
[13] E. Maverakis,et al. Interactions of the Immune System with Skin and Bone Tissue in Psoriatic Arthritis: A Comprehensive Review , 2016, Clinical Reviews in Allergy & Immunology.
[14] M. Marenzana,et al. Refine, reduce, replace: Imaging of fibrosis and arthritis in animal models. , 2015, Best practice & research. Clinical rheumatology.
[15] Wei Tang,et al. Toll-like receptors: potential targets for lupus treatment , 2015, Acta Pharmacologica Sinica.
[16] C. Ritchlin,et al. Etiology and Pathogenesis of Psoriatic Arthritis. , 2015, Rheumatic diseases clinics of North America.
[17] R. Furie,et al. Lessons Learned From the Clinical Trials of Novel Biologics and Small Molecules in Lupus Nephritis. , 2015, Seminars in nephrology.
[18] D. D'cruz,et al. Key issues in the management of patients with systemic lupus erythematosus: latest developments and clinical implications , 2015, Therapeutic advances in musculoskeletal disease.
[19] Mark Asquith,et al. The intestinal microbiome in spondyloarthritis , 2015, Current opinion in rheumatology.
[20] G. Huber,et al. Morphological and biomechanical analyses of the subchondral mineralized zone in human sacral facet joints: Application to improved diagnosis of osteoarthritis , 2015, Clinical anatomy.
[21] M. Brown,et al. The intestinal microbiome in human disease and how it relates to arthritis and spondyloarthritis. , 2015, Best practice & research. Clinical rheumatology.
[22] Kenneth G. C. Smith,et al. Emerging concepts in the pathogenesis of antineutrophil cytoplasmic antibody-associated vasculitis , 2015, Current opinion in rheumatology.
[23] A. Ogdie,et al. Recognizing and managing comorbidities in psoriatic arthritis , 2015, Current opinion in rheumatology.
[24] R. Ferriols-Lisart,et al. Dose modifications of anti-TNF drugs in rheumatoid arthritis patients under real-world settings: a systematic review , 2015, Rheumatology International.
[25] P. Merkel,et al. Outcome measures for Takayasu's arteritis , 2015, Current opinion in rheumatology.
[26] G. Tómasson. Outcome measures for antineutrophil cytoplasmic antibody-associated vasculitis , 2015, Current opinion in rheumatology.
[27] Raveendhara R. Bannuru,et al. American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis , 2015 .
[28] A. Armstrong,et al. Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with Psoriasis , 2014, Drugs.
[29] Désirée van der Heijde,et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update , 2013, Annals of the rheumatic diseases.
[30] M. Weisman,et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012 , 2013, Annals of the rheumatic diseases.
[31] D. Isenberg,et al. B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design , 2013, Arthritis Research & Therapy.
[32] F. Breedveld,et al. antirheumatic drugs: 2013 update synthetic and biological disease-modifying management of rheumatoid arthritis with EULAR recommendations for the , 2013 .
[33] M. Weisman,et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010 , 2011, Annals of the rheumatic diseases.
[34] R. Stasi. An overview of pharmacotherapy for anti-neutrophil cytoplasmic antibody-associated vasculitis. , 2010, Drugs of today.
[35] F. Breedveld,et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. , 2006, Arthritis and rheumatism.
[36] A. McMahon,et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial , 2004, The Lancet.